NASDAQ:ZIOP - ZIOPHARM Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.86 +0.17 (+6.32 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$2.86
Today's Range$2.65 - $2.92
52-Week Range$2.23 - $6.67
Volume880,414 shs
Average Volume1.44 million shs
Market Capitalization$420.02 million
P/E Ratio-5.40
Dividend YieldN/A
Beta1.33
ZIOPHARM Oncology logoZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970

Debt

Debt-to-Equity RatioN/A
Current Ratio5.69
Quick Ratio5.69

Price-To-Earnings

Trailing P/E Ratio-5.40
Forward P/E Ratio-5.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.39 million
Price / Sales63.73
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-4.21

Profitability

EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-61.17%

Miscellaneous

Employees46
Outstanding Shares142,380,000
Market Cap$420.02 million

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.12) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.12). View ZIOPHARM Oncology's Earnings History.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for ZIOPHARM Oncology.

What price target have analysts set for ZIOP?

3 analysts have issued 12-month price targets for ZIOPHARM Oncology's shares. Their forecasts range from $5.50 to $5.50. On average, they expect ZIOPHARM Oncology's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.

What is the consensus analysts' recommendation for ZIOPHARM Oncology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ZIOPHARM Oncology.

What are Wall Street analysts saying about ZIOPHARM Oncology stock?

Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
  • 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
  • 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)

Are investors shorting ZIOPHARM Oncology?

ZIOPHARM Oncology saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 35,724,966 shares, an increase of 0.7% from the July 13th total of 35,489,971 shares. Based on an average daily trading volume, of 1,235,509 shares, the days-to-cover ratio is presently 28.9 days. Approximately 27.5% of the company's stock are short sold. View ZIOPHARM Oncology's Current Options Chain.

Who are some of ZIOPHARM Oncology's key competitors?

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:
  • Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
  • Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 62)
  • Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
  • Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
  • Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.

Has ZIOPHARM Oncology been receiving favorable news coverage?

Press coverage about ZIOP stock has been trending somewhat negative on Saturday, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a news and rumor sentiment score of -0.01 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for ZIOPHARM Oncology.

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.43%), Miller Value Partners LLC (3.45%), Schwab Charles Investment Management Inc. (0.50%), Vident Investment Advisory LLC (0.41%), Bank of America Corp DE (0.07%) and Chessman Wealth Strategies RIA (0.05%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.

Which institutional investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including Miller Value Partners LLC. View Insider Buying and Selling for ZIOPHARM Oncology.

Which institutional investors are buying ZIOPHARM Oncology stock?

ZIOP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Vident Investment Advisory LLC, Chessman Wealth Strategies RIA, Schwab Charles Investment Management Inc., Raymond James & Associates and MetLife Investment Advisors LLC. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $2.86.

How big of a company is ZIOPHARM Oncology?

ZIOPHARM Oncology has a market capitalization of $420.02 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. ZIOPHARM Oncology employs 46 workers across the globe.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]


MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.